PMID: 9426699Jan 14, 1998Paper

Ratio of IgG:IgM antibodies to sialyl Lewis(x) and GM3 correlates with tumor growth after immunization with melanoma-cell vaccine with different adjuvants in mice

International Journal of Cancer. Journal International Du Cancer
M H RavindranathD L Morton

Abstract

Human melanoma cells (from biopsies and culture) express sialyl-Lewis(x) and sialyl Lewis(a), the ligands for ECAM. These ligands may facilitate tumor progression and metastasis in human cancers. To test whether the antibodies to these ligands inhibit tumor progression, IgG and IgM responses to sLe(x) and sLe(a) were induced in C57BL/6j mice (n = 76) by immunization with human melanoma cells, with or without adjuvants (BCG, MPL, KLH). Control mice were treated with saline or BCG. Tumor growth and antigen expression were monitored after challenge with B16 mouse melanoma cells expressing sLe(x), sLe(a) and the ganglioside GM3. Tumor growth was reduced in mice immunized with BCG alone or cells with BCG or MPL, while tumors in mice receiving cells without adjuvants grew larger than in the control. Augmentation of IgM titers to sLe(x) and GM3 after immunization with BCG, or with cells with BCG or MPL correlated with retarded tumor growth, while increased IgG titers to sLe(x) significantly correlated with aggressive tumor growth in mice immunized with cells without adjuvants. SLe(x), sLe(a) and GM3 were expressed in tumors from mice treated with saline or BCG. SLe(x) expression, in particular, was lost in tumors growing in mice immun...Continue Reading

References

Jan 1, 1978·Advances in Cancer Research·R W Baldwin, M V Pimm
Apr 1, 1991·Journal of Leukocyte Biology·Y F ChenA G Johnson
Apr 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·C V HardingE R Unanue
Nov 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D BerdM J Mastrangelo
May 1, 1988·Infection and Immunity·P J BakerJ A Rudbach
Mar 10, 1994·Journal of Immunological Methods·M H RavindranathM C Graves
May 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P O LivingstonG Ritter
Jun 1, 1993·Journal of Autoimmunity·M L FreimerD B Drachman
May 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·R T Prehn
Jan 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M KirkwoodR H Blum

❮ Previous
Next ❯

Citations

Mar 14, 2013·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Pei-Yu LiangShan-Ji Ou
Jul 15, 1999·Nature Biotechnology·T Kieber-EmmonsZ Steplewski
Apr 16, 2014·Proceedings of the National Academy of Sciences of the United States of America·Christopher T CampbellJeffrey C Gildersleeve
Mar 30, 2004·The Journal of Biological Chemistry·Wei ZouHarold J Jennings
Jan 22, 2010·Expert Opinion on Biological Therapy·Mayrel LabradaLuis E Fernández
Jan 7, 2015·Journal of Asian Natural Products Research·Jian-Wei ChenHong Wang
Apr 30, 2016·Scientific Reports·Beata UjvariThomas Madsen
Oct 19, 1999·Microbiology and Immunology·N Okada, H Okada
Feb 9, 2005·DNA and Cell Biology·Yue-Jin WenThomas Kieber-Emmons
Nov 2, 1999·Micron : the International Research and Review Journal for Microscopy·J R Harris, J Markl
Oct 4, 2011·Vaccine·Jamie Heimburg-MolinaroKate Rittenhouse-Olson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antigenic Modulation

Antigenic modulation occurs when an antibody cross-links antigens on a cell surface, causing the antigens to become internalized. This can lead to therapeutic failure of monoclonal antibodies as the expression of the antigen becomes decreased on target cells. Find the latest research on antigenic modulation here.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.